Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesFate Therapeutics Inc

Fate Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.605 USD -0.17 ( 9.32%)
Last update at 2026-11-11T21:00:00Z
VOLUME
2595269
Market Cap
156.96M

Momentum Score

…

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.60
Low
1.79
High
52 Week Price Range
0.91
Low
1.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Fate Therapeutics is a clinical-stage biopharmaceutical developing off-the-shelf cell therapies from induced pluripotent stem cells (iPSCs) to produce NK and T cell candidates for cancer and immune disorders. Long-term growth may be supported by clinical readouts, regulatory progress and manufacturing scale-up of its allogeneic platform, while a diversified pipeline could appeal to investors.

Key risks include clinical and regulatory setbacks, high cash burn with likely need for additional financing, manufacturing complexity for iPSC-derived products and intense competition from other cell therapy developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.77
Dividend Yield
-
Revenue TTM
6.65M
Revenue Per Share
0.06
Gross Profit TTM
-85.25M
Debt / Equity
0.38
ROE
-51.84%
Net Debt
31.22M
ROCE
-48.19%
Diluted EPS TTM
-1.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -136.31M -186.26M -160.93M -281.72M -212.15M
Net income -136.31M -186.26M -160.93M -255.06M -206.30M
Selling general administrative 46.52M 74.17M 81.45M 84.23M 57.32M
Selling and marketing expenses - - 15.41M - -
Gross profit -6.25M 13.63M -93.65M 96.30M 55.85M
Reconciled depreciation 12.90M 18.96M 18.24M 13.76M 5.85M
Ebit -136.31M -195.54M -190.51M -322.14M -216.99M
Ebitda -127.02M -176.58M -172.23M -308.39M -215.69M
Depreciation and amortization 9.29M 18.96M 18.28M 13.76M 1.31M
Non operating income net other - - - - 4.84M
Operating income -147.70M -210.28M -190.51M -308.39M -216.99M
Other operating expenses 154.35M 223.91M 254.04M 404.69M 272.84M
Interest expense - - - 5.84M 4.54M
Interest income 11.05M 17.29M 15.65M 5.84M 1.31M
Net interest income 11.05M 17.29M 15.65M 5.84M 1.31M
Income tax expense - - 18.11M -26.66M -5.85M
Total revenue 6.65M 13.63M 63.53M 96.30M 55.85M
Total operating expenses 141.45M 223.91M 96.86M 404.69M 272.84M
Cost of revenue 12.90M 18.96M 157.19M - -
Total other income expense net 11.39M 24.01M 29.58M 26.66M 4.84M
Net income from continuing ops -136.31M -186.26M -173.17M -281.72M -212.15M
Net income applicable to common shares - - - -281.72M -212.15M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 318.94M 440.69M 506.22M 705.56M 921.46M
Other current assets 4.13M 9.30M 13.64M 27.37M 8.83M
Total liab 111.75M 121.97M 137.80M 221.62M 242.62M
Total stockholder equity 207.18M 318.73M 368.42M 483.94M 678.84M
Deferred long term liab - - - 7.20M 9.87M
Other current liab 28.47M 21.35M 27.51M 57.93M 45.61M
Common stock 0.12M 0.11M 0.10M 0.10M 0.10M
Capital stock 0.12M 0.12M 0.10M 0.10M 0.10M
Retained earnings -1534.31M -1397.99M -1211.73M -1050.80M -769.08M
Other liab - - - 3.86M 52.09M
Other assets - - 0.00M 22.46M 25.13M
Cash 46.63M 36.06M 41.87M 61.33M 133.58M
Total current liabilities 36.07M 38.52M 39.09M 114.05M 81.28M
Current deferred revenue 0.38M 0.39M 0.69M 42.23M 21.48M
Net debt 31.22M 49.21M 61.67M 48.01M -18.77M
Short term debt 4.56M 7.42M 6.18M 5.63M 5.58M
Short long term debt total 77.85M 85.27M 103.54M 109.34M 114.82M
Other stockholder equity 1741.26M 1716.34M 1580.03M 1536.50M 1448.58M
Property plant equipment - - - 176.09M 162.25M
Total current assets 208.70M 291.91M 331.54M 502.07M 633.41M
Long term investments 1.47M 27.66M 0.98M 4.94M 100.66M
Net tangible assets - - - 483.94M 678.84M
Short term investments 157.03M 243.01M 273.31M 374.89M 482.33M
Net receivables 0.92M 3.54M 2.73M 38.48M 8.68M
Accounts payable 2.66M 9.37M 4.72M 8.27M 8.61M
Accumulated other comprehensive income 0.12M 0.27M 0.01M -1.85M -0.76M
Common stock total equity - - - - 0.10M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - -769.08M
Non currrent assets other 10.23M 10.24M 0.01M 132.48M 116.66M
Non current assets total 110.23M 148.78M 174.68M 203.49M 288.04M
Capital lease obligations 77.85M 85.27M 103.54M 109.34M 114.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 116.76M 12.22M 120.42M 166.75M -273.32M
Change to liabilities - - - 14.25M 5.91M
Total cashflows from investing activities 111.17M 12.22M 112.67M 166.75M -324.02M
Total cash from financing activities 5.49M 99.89M 0.09M 9.21M 453.13M
Change to operating activities - - - -19.16M -0.65M
Net income -136.31M -186.26M -160.93M -281.72M -212.15M
Change in cash 10.57M -5.81M -19.46M -72.25M -33.76M
Begin period cash flow 46.28M 41.87M 61.33M 148.81M 182.57M
End period cash flow 56.85M 36.06M 41.87M 76.56M 148.81M
Total cash from operating activities -106.08M -122.87M -132.26M -248.21M -162.87M
Issuance of capital stock 0.00M 74.53M 0.00M 0.00M 411.74M
Depreciation 9.29M 18.96M 18.28M 13.76M 5.85M
Other cashflows from investing activities 0.36M - - - -
Change to inventory - - - - -5.91M
Change to account receivables 2.62M -1.11M 36.65M -29.80M -3.16M
Sale purchase of stock - - - - 432.45M
Other cashflows from financing activities 5.49M 5.07M 0.09M 166.75M 41.39M
Change to netincome - - - 51.79M 37.34M
Capital expenditures 5.95M 0.73M 6.15M 35.57M 50.70M
Change receivables - - - - -3.16M
Cash flows other operating - - - - -18.75M
Cash and cash equivalents changes - - - - -33.76M
Change in working capital -3.74M -1.96M 19.18M -34.71M 2.10M
Stock based compensation 24.92M 41.50M 43.46M 78.73M 54.36M
Other non cash items -0.25M 4.89M -52.26M -24.27M -18.10M
Free cash flow -112.04M -123.60M -138.42M -283.77M -213.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FATE
Fate Therapeutics Inc		 -0.17
9.32%		 1.60 - - 23.62 0.78 5.39 -2.59
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

12278 Scripps Summit Drive, San Diego, CA, United States, 92131

858 875 1800

https://www.fatetherapeutics.com

161

Name Title Year Born
Mr. J. Scott Wolchko Founder, CEO, Pres & Director 1970
Mr. Edward J. Dulac III Chief Financial Officer 1976
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technical Officer 1961
Ms. Cindy R. Tahl Gen. Counsel & Corp. Sec. 1973
Dr. Bahram Valamehr Ph.D. Chief R&D Officer 1977
Dr. Yu-Waye Chu M.D. Chief Medical Officer NA
Mr. Jim Beitel M.B.A. Sr. VP of Corp. Devel. NA
Dr. Sarah Cooley Sr. VP of Clinical Translation NA
Dr. Jerome Bressi Ph.D. Sr. VP of Regulatory Affairs & Quality NA
Mr. Brian T. Powl M.B.A., M.S. Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…